The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, Shandong, from September 10 to 14, 2025, under the theme “Standardized Treatment, Innovation-Driven Progress.” The meeting gathered leading scholars from China and abroad for a major exchange of ideas. In the field of breast cancer, Professor Giuseppe Curigliano, President-Elect of the European Society for Medical Oncology (ESMO) and Professor at the University of Milan, shared the revolutionary progress of antibody-drug conjugates (ADCs). Professor Zefei Jiang, President-Elect of CSCO and oncologist at the General Hospital of the PLA, presented Chinese subgroup data from the DESTINY-Breast09 (DB09) study, which investigated first-line treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab for HER2-positive advanced breast cancer, highlighting the bright future of ADC therapy. The two experts sat down with Oncology Frontier to discuss the promising outlook for CSCO–ESMO collaboration and to interpret the clinical impact of DESTINY-Breast09.

Editor’s Note: Immunotherapy has become an important treatment modality in breast cancer, achieving breakthroughs by modulating the immune system to mount anti-tumor responses. At the 8th Conference on Oncology Precision…

Editor’s Note: The 13th Lu Daopei Hematology Forum, jointly organized by the Beijing Health Promotion Association and the Guangzhou Hongmian Cancer and Rare Disease Foundation and hosted by the Beijing…